{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T05:38:54Z","timestamp":1777354734768,"version":"3.51.4"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hepatitis B virus (HBV) reactivation after transcatheter Arterial Chemoembolization (TACE) can lead to severe complications and affect prognosis. Current research on HBV reactivation following TACE is limited and inconsistent. Long-term prognostic data on antiviral therapy (AVT) in patients undergoing TACE are also scarce.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>This study aimed to evaluate the risk factors for HBV reactivation in hepatitis B surface antigen (HBsAg) positive Hepatocellular carcinoma (HCC) patients following TACE and the impact of prophylactic AVT on HBV reactivation and survival outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>This retrospective study included HBsAg-positive, treatment-naive HCC patients who underwent TACE between December 2020 and December 2024. Patient baseline characteristics, TACE procedures, and follow-up data were collected. HBV reactivation was defined as a \u22652 log IU\/mL increase in HBV DNA levels from baseline or HBsAg seroconversion. Prophylactic AVT was defined as anti-HBV drug administration before or during TACE, continued throughout follow-up. Survival outcomes were assessed using the Kaplan-Meier method, log-rank test and Cox proportional hazards regression analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 168 patients were enrolled. HBV reactivation occurred in 32 patients (19.0%). Multivariate analysis identified the absence of prophylactic AVT (odds ratio [OR] 3.56, 95% CI 1.55-8.18, P\u00a0=\u00a00.003) and chemotherapeutic agents (&amp;gt;2 agents) (OR 2.79, 95% CI 1.09-7.14, P\u00a0=\u00a00.032) as independent risk factors for HBV reactivation. Unadjusted Kaplan\u2013Meier analysis showed that patients without HBV reactivation had significantly better OS (P\u00a0=\u00a00.036). Multivariable Cox proportional hazards regression analysis confirmed that HBV reactivation (hazard ratio [HR]=1.43, 95%CI:0.90\u20132.28, P\u00a0=\u00a00.047) and macrovascular invasion (HR\u00a0=\u00a01.69, 95%CI:1.14\u20132.51, P\u00a0=\u00a00.017) were independent predictors of poor OS, whereas prophylactic AVT was not significantly associated with OS (HR\u00a0=\u00a00.75, 95%CI:0.50\u20131.14, P\u00a0=\u00a00.182).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In HBsAg-positive HCC patients undergoing TACE, the absence of prophylactic AVT and chemotherapeutic agents (&amp;gt;2 agents) are significant risk factors for HBV reactivation. HBV reactivation and macrovascular invasion are independent predictors of poor OS, while prophylactic AVT shows no significant association with OS. These findings provide real-world evidence for optimizing the clinical management of HBV-related HCC patients undergoing TACE.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1818955","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T04:46:36Z","timestamp":1777351596000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["HBV reactivation in HCC patients following TACE: risk factors, antiviral therapy impact, and survival analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Hao","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Interventional Radiology, The Seventh Affiliated Hospital of Sun Yat-sen University","place":["Shenzhen, Guangdong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia-Hang","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology, The Seventh Affiliated Hospital of Sun Yat-sen University","place":["Shenzhen, Guangdong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-Yong","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology, The Seventh Affiliated Hospital of Sun Yat-sen University","place":["Shenzhen, Guangdong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"De-Di","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology, The Seventh Affiliated Hospital of Sun Yat-sen University","place":["Shenzhen, Guangdong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology, The Seventh Affiliated Hospital of Sun Yat-sen University","place":["Shenzhen, Guangdong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-Yong","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology, The First Affiliated Hospital, Sun Yat-Sen University","place":["Guangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-Hui","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology, The First Affiliated Hospital, Sun Yat-Sen University","place":["Guangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying\u2212Qiang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology, The Seventh Affiliated Hospital of Sun Yat-sen University","place":["Shenzhen, Guangdong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30427-1","article-title":"Mortality, morbidity, and risk factors in China and its provinces, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"394","author":"Zhou","year":"2019","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21338","article-title":"Cancer statistics in China, 2015","volume":"66","author":"Chen","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-004-0552-0","article-title":"Randomized controlled trial of screening for hepatocellular carcinoma","volume":"130","author":"Zhang","year":"2004","journal-title":"J Cancer Res Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"16018","DOI":"10.1038\/nrdp.2016.18","article-title":"Hepatocellular carcinoma","volume":"2","author":"Llovet","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.33156","article-title":"Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma","volume":"35","author":"Lo","year":"2002","journal-title":"Hepatology"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3348\/kjr.2009.10.5.425","article-title":"The current practice of transarterial chemoembolization for the treatment of hepatocellular carcinoma","volume":"10","author":"Shin","year":"2009","journal-title":"Korean J Radiol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s00270-015-1208-y","article-title":"Treatment of liver tumors with lipiodol TACE: technical recommendations from experts opinion","volume":"39","author":"de Baere","year":"2016","journal-title":"Cardiovasc Intervent Radiol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1385\/MO:21:1:67","article-title":"Reactivation of hepatitis B virus\u00a0infection with cytotoxic therapy in non-hodgkin\u2019s lymphoma","volume":"21","author":"Ozguroglu","year":"2004","journal-title":"Med Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06465.x","article-title":"Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies","volume":"136","author":"Lalazar","year":"2007","journal-title":"Br J Haematol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-015-9612-6","article-title":"Preemptive adefovir versus lamivudine for prevention of hepatitis B reactivation in chronic hepatitis B patients undergoing chemotherapy","volume":"9","author":"Ho","year":"2015","journal-title":"Hepatol Int"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-011-9279-6","article-title":"Hepatitis B virus reactivation in patients receiving cancer chemotherapy: natural history, pathogenesis, and management","volume":"7","author":"Liu","year":"2013","journal-title":"Hepatol Int"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.12898","article-title":"Hepatitis B viral load predicts survival in hepatocellular carcinoma patients treated with sorafenib","volume":"30","author":"Lim","year":"2015","journal-title":"J Gastroenterol Hepatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12805","article-title":"A high baseline HBV load and antiviral therapy affect the survival of patients with advanced HBV-related HCC treated with sorafenib","volume":"35","author":"Yang","year":"2015","journal-title":"Liver Int"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2007.04.005","article-title":"Hepatitis B virus reactivation after three-dimensional conformal radiotherapy in patients with hepatitis B virus-related hepatocellular carcinoma","volume":"69","author":"Kim","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2004.05.014","article-title":"Transarterial chemo-lipiodolization can reactivate hepatitis B virus replication in patients with hepatocellular carcinoma","volume":"41","author":"Jang","year":"2004","journal-title":"J Hepatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1872-034X.2011.00796.x","article-title":"Changes in hepatitis B virus DNA levels and liver function after transcatheter arterial chemoembolization of hepatocellular carcinoma","volume":"41","author":"Lao","year":"2011","journal-title":"Hepatol Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2005.00232.x","article-title":"Risk of hepatitis B exacerbation is low after transcatheter arterial chemoembolization therapy for patients with HBV-related hepatocellular carcinoma: report of a prospective study","volume":"100","author":"Park","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1097\/sla.0000000000000858","article-title":"Antiviral therapy improves postoperative survival in patients with hepatocellular carcinoma: a randomized controlled trial","volume":"261","author":"Huang","year":"2015","journal-title":"Ann Surg"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i20.6006","article-title":"Impact of antiviral therapy on post-hepatectomy outcome for hepatitis B-related hepatocellular carcinoma","volume":"20","author":"Chong","year":"2014","journal-title":"World J Gastroenterol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s40880-016-0089-z","article-title":"Association of HBV DNA replication with antiviral treatment outcomes in the patients with early-stage HBV-related hepatocellular carcinoma undergoing curative resection","volume":"35","author":"Chen","year":"2016","journal-title":"Chin J Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz860","article-title":"Association of prophylactic anti-HBV therapy with improved long-term survival in patients with\u00a0hepatocellular carcinoma undergoing transarterial therapy","volume":"71","author":"Jang","year":"","journal-title":"Clin Infect Dis"},{"key":"B23","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL clinical practice guidelines: management of hepatocellular carcinoma","volume":"69","year":"2018","journal-title":"J Hepatol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatol (Baltim Md)"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.4061\/2011\/416459","article-title":"The role of antiviral therapy for HBV-related hepatocellular carcinoma","volume":"2011","author":"Yu","year":"2011","journal-title":"Int J Hepatol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2004.07.005","article-title":"Out of control: hepatitis B reactivation by transarterial treatment of hepatocellular carcinoma","volume":"41","author":"von Weizs\u00e4cker","year":"2004","journal-title":"J Hepatol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/2931402","article-title":"Recent advances in HBV reactivation research","volume":"2018","author":"Guo","year":"2018","journal-title":"BioMed Res Int"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-148-7-200804010-00008","article-title":"Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy","volume":"148","author":"Loomba","year":"2008","journal-title":"Ann Intern Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1073\/pnas.0913498107","article-title":"Immune effectors required for hepatitis B virus clearance","volume":"107","author":"Yang","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"B30","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s12032-017-0917-2","article-title":"New concepts in embolotherapy of HCC","volume":"34","author":"Pesapane","year":"2017","journal-title":"Med Oncol (Northwood Lond Engl)"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.14218\/jcth.2023.00320","article-title":"Guidelines for the prevention and\u00a0treatment of chronic hepatitis B (version 2022)","volume":"11","author":"You","year":"2023","journal-title":"J Clin Transl Hepatol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyz046","article-title":"Effects of TACE and preventive antiviral therapy on HBV reactivation and subsequent hepatitis in hepatocellular carcinoma: a meta-analysis","volume":"49","author":"Zhang","year":"2019","journal-title":"Jpn J Clin Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.582504","article-title":"Effects of antiviral therapy on HBV reactivation and survival in hepatocellular carcinoma patients undergoing hepatic artery infusion chemotherapy","volume":"10","author":"Liu","year":"2020","journal-title":"Front Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2013.03.020","article-title":"Hepatitis B virus reactivation after radiofrequency ablation or hepatic resection for HBV-related small hepatocellular carcinoma: a retrospective study","volume":"39","author":"Dan","year":"2013","journal-title":"Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.2147\/tcrm.s91618","article-title":"The hepatitis B virus reactivation after transarterial chemoembolization in chinese hepatocellular carcinoma patients with low serum hepatitis B virus DNA level","volume":"11","author":"Shao","year":"2015","journal-title":"Ther Clin Risk Manag"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-014-2881-1","article-title":"Nucleos(t)ide analogue therapy for HBV-related HCC after hepatic resection: clinical benefits and unanswered questions","volume":"35","author":"Zhong","year":"2014","journal-title":"Tumour Biol J Int Soc Oncodevelopmental Biol Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v99.7.2324","article-title":"High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation","volume":"99","author":"Lau","year":"2002","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1046\/j.1352-0504.2003.00467.x","article-title":"High hepatitis B virus (HBV) DNA viral load is an important risk factor for HBV reactivation in breast cancer patients undergoing cytotoxic chemotherapy","volume":"11","author":"Zhong","year":"2004","journal-title":"J Viral Hepat"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh430","article-title":"Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy","volume":"15","author":"Yeo","year":"2004","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i34.12039","article-title":"Hepatitis B viral load affects prognosis of hepatocellular carcinoma","volume":"20","author":"Yu","year":"2014","journal-title":"World J Gastroenterol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.jcv.2013.08.012","article-title":"Rates and risk factors for hepatitis B reactivation in a cohort of persons in the inactive phase of chronic hepatitis B-alaska, 2001-2010","volume":"58","author":"Tohme","year":"2013","journal-title":"J Clin Virol Off Publ Pan Am Soc Clin Virol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1818955\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T04:46:42Z","timestamp":1777351602000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1818955\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":41,"alternative-id":["10.3389\/fonc.2026.1818955"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1818955","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,28]]},"article-number":"1818955"}}